Vector Borne Diseases: Clinical Trials

20 trials for Vector Borne Diseases, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

10 completed, 3 unknown, 2 not yet recruiting, 2 recruiting. 20 Early Phase 1.

By phase and status

PhaseTrialsStatus
Early Phase 120Completed 10, Unknown 3, Not yet recruiting 2, Recruiting 2, Terminated 2, Active not recruiting 1

Follow Vector Borne Diseases: new trials by email Literature Review of Vector Borne Diseases trials Research Report on Vector Borne Diseases

Trials (filtered) newest first · largest first

All 20 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Phase I Study of PepGNP-ChikV in Healthy Volunteers
PepGNP-ChikV, Placebo - Chikungunya, Chikungunya Fever
Early Phase 1Not yet recruitingGylden Pharma Ltd402026-08-032026-04-29
Focal Mass Drug Administration for the Prevention of Malaria in Pregnancy
Dihydroartemisinin Piperaquine - Malaria Prevention
Early Phase 1RecruitingUniversity of North Carolina, Chapel Hill3002026-04-222026-11-03
Safety, Virological and Immunological Assessment of the Controlled Dengue Human Infection Model in Dengue-Immune Participants in Thailand (DHIT-Immune)
rDEN2Δ30-7169 - Safety Issues, Dengue
Early Phase 1Not yet recruitingMahidol University122025-09-012025-04-03
Immunogenicity of an Intradermal Qdenga Vaccine Among Healthy Volunteers
Vaccine - Dengue
Early Phase 1CompletedPrince of Songkla University292025-04-192026-10-02
Ceftriaxone Pulse Dose for Post-Treatment Lyme Disease
Ceftriaxone (Rocephin®), Dextrose 5% (D5W) - Post-Treatment Lyme Disease
Early Phase 1RecruitingState University of New York - Upstate Medical University442025-02-032026-03-19
Coadministration of GA2 Sporozoites With Adjuvants
GA2, BCG, YF-17D (fractional ID dose) - Malaria,Falciparum
Early Phase 1UnknownLeiden University Medical Center452023-02-032023-02-10
A Phase Ia Clinical Trial to Assess the Safety and Immunogenicity of the Blood-stage Malaria Candidate Vaccines RH5.1 in Matrix-M and R78C in Matrix-M in Healthy UK Adults
Matrix M with R78C and/or RH5.1 - Malaria, Falciparum
Early Phase 1Active not recruitingUniversity of Oxford362023-01-132025-04-01
A Study of the Plasmodium Falciparum Malaria Vaccine Candidate Pfs48/45 in Matrix-M Adjuvant in the UK
Pfs48/45 in Matrix-M - Malaria, Plasmodium Falciparum
Early Phase 1TerminatedUniversity of Oxford172022-11-022026-08-07
Safety, Virological and Immunological Assessment of Live Attenuated Dengue Serotype 2 rDEN2delta30-7169.
rDEN2Δ30-7169 - Dengue
Early Phase 1UnknownMahidol University52022-08-012022-07-27
Safety and Immunogenicity of Pvs25-IMX313/Matrix-M1 Vaccine
Pvs25-IMX313/Matrix-M1 - Malaria, Vivax
Early Phase 1TerminatedUniversity of Oxford252022-02-092026-01-15
Safety and Immunogenicity of a Candidate RVFV Vaccine (RVF001)
ChAdOx1 RVF - Rift Valley Fever
Early Phase 1CompletedUniversity of Oxford152021-06-112023-05-19
VAC069: A Study of Blood-stage Controlled Human P. Vivax Infection
P. vivax infected inoculum (parasitised red blood cells) - Malaria, Vivax
Early Phase 1CompletedUniversity of Oxford192019-01-102025-04-25
Study Assessing Pharmacokinetics and Bioavailability of Three Novel Triazine Compounds
WR826647, WR909388, WR909390 - Malaria
Early Phase 1CompletedU.S. Army Medical Research and Development Command182018-08-102019-03-05
Resistance Exercise Program on the Functionality of Individuals With Chikungunya Fever
Resistance exercise - Chikungunya Fever
Early Phase 1UnknownUniversidade Federal de Pernambuco302018-07-232019-09-27
Effects of Omega-3 Supplementation on the Cytokine and Lipid Profiles in Patients With Chronic Chagas Cardiomyopathy
Omega-3, Placebo Comparator - Chagas Cardiomyopathy
Early Phase 1CompletedEvandro Chagas Institute of Clinical Research402013-03-012016-09-09
Efficacy of Topical Liposomal Form of Drugs in Cutaneous Leishmaniasis
Liposomal meglumine antimoniate (Glucantime), Liposomal meglumine antimoniate, Liposomal Paromomycin - Cutaneous Leishmaniasis
Early Phase 1CompletedTehran University of Medical Sciences302011-03-012012-06-20
Searching for Persistence of Infection in Lyme Disease
Lyme Disease Xenodiagnosis - Lyme Disease
Early Phase 1CompletedNational Institute of Allergy and Infectious Diseases (NIAID)452010-11-042026-10-16
Differences in Malaria Infection Levels in HIV-infected Infants and Children Receiving PI- and NNRTI-based HAART
Lamivudine, Lopinavir/Ritonavir, Nevirapine - HIV Infections, Malaria
Early Phase 1CompletedInternational Maternal Pediatric Adolescent AIDS Clinical Trials Group1052009-08-012016-09-19
Study of Iron Absorption and Utilization in Asymptomatic Malaria
Antimalarial treatment, Observation - Malaria, Falciparum
Early Phase 1CompletedSwiss Federal Institute of Technology232009-02-012013-06-07
Establishment of a Sporozoite Challenge Model for Plasmodium Vivax in Human Volunteers
Sporozoite Challenge Model for Plasmodium vivax in Humans - Malaria, Vivax
Early Phase 1CompletedMalaria Vaccine and Drug Development Center182005-01-012010-03-09

Narrower conditions

Malaria (6)  ·  Malaria, Falciparum (4)  ·  Dengue (3)  ·  Malaria, Vivax (3)  ·  Chikungunya Fever (2)  ·  Chagas Cardiomyopathy (1)  ·  Chagas Disease (1)  ·  Coinfection (1)  ·  Communicable Diseases (1)  ·  HIV Infections (1)  ·  Leishmaniasis, Cutaneous (1)  ·  Lyme Disease (1)  ·  Post-Lyme Disease Syndrome (1)  ·  Rift Valley Fever (1)  ·  Viremia (1)

Broader conditions

Infections (20)  ·  Mosquito-Borne Diseases (16)  ·  Parasitic Diseases (12)  ·  Protozoan Infections (12)  ·  RNA Virus Infections (7)  ·  Virus Diseases (7)  ·  Arbovirus Infections (6)  ·  Hemorrhagic Fevers, Viral (4)  ·  Malaria (4)  ·  Flaviviridae Infections (3)  ·  Flavivirus Infections (3)  ·  Pathologic Processes (3)  ·  Pathological Conditions, Signs and Symptoms (3)  ·  Alphavirus Infections (2)

Interventions

Matrix-M (3)  ·  Ceftriaxone (1)  ·  Corn Oil (1)  ·  Docosahexaenoic Acids (1)  ·  Fatty Acids, Omega-3 (1)  ·  Fatty Acids, Unsaturated (1)  ·  Fish Oils (1)  ·  Glucose (1)  ·  Imiquimod (1)  ·  Lamivudine (1)  ·  Lopinavir (1)  ·  Meglumine Antimoniate (1)  ·  Nevirapine (1)  ·  Observation (1)  ·  Resistance Training (1)

Sponsors

University of Oxford (5)  ·  Mahidol University (2)  ·  Evandro Chagas Institute of Clinical Research (1)  ·  Gylden Pharma Ltd (1)  ·  International Maternal Pediatric Adolescent AIDS Clinical Trials Group (1)  ·  Leiden University Medical Center (1)  ·  Malaria Vaccine and Drug Development Center (1)  ·  National Institute of Allergy and Infectious Diseases (NIAID) (1)  ·  Prince of Songkla University (1)  ·  State University of New York - Upstate Medical University (1)  ·  Swiss Federal Institute of Technology (1)  ·  Tehran University of Medical Sciences (1)  ·  U.S. Army Medical Research and Development Command (1)  ·  Universidade Federal de Pernambuco (1)  ·  University of North Carolina, Chapel Hill (1)

Countries

United Kingdom (5)  ·  United States (3)  ·  Brazil (2)  ·  Thailand (2)  ·  Uganda (2)  ·  Benin (1)  ·  Colombia (1)  ·  Iran (1)  ·  Malawi (1)  ·  Netherlands (1)  ·  Zambia (1)

Top investigators

Angela M Minassian, DPhil FRCP (3)  ·  Adrian VS Hill, Prof (1)  ·  Adriana R Marques, M.D. (1)  ·  Ali Khamesipour, MPH, PhD (1)  ·  Allen Hunt, MD (1)  ·  Andrea S Sousa, MD PhD (1)  ·  Angela M Minassian, MBBS MA DPhil MRCP FRCPath (1)  ·  Charlotte Hobbs, MD (1)  ·  Kristopher Paolino, MD (1)  ·  Mahmoud Reza Jaafari, Parm D, PhD (1)  ·  Masud Maleki, MD (1)  ·  Meta Roestenberg, MD, PhD (1)  ·  Michael Zimmermann, Prof., MD (1)  ·  Ross Boyce, MD (1)  ·  Socrates Herrera, MD (1)

Results publications

PMID 11716100, PMID 11741694, PMID 11816444, PMID 12171615, PMID 12476490, PMID 13356045, PMID 14579464, PMID 14582335, PMID 1688828, PMID 20926522, PMID 2094597, PMID 24216069, PMID 24523212, PMID 27936233, PMID 28599665, PMID 34609964, PMID 3511753, PMID 35664997, PMID 37060917, PMID 37616070, PMID 39753962, PMID 40998768, PMID 4590095, PMID 7475658, PMID 7660433, PMID 7785527, PMID 7845714, PMID 7932927, PMID 808142, PMID 8357078, PMID 8376823, PMID 8842108, PMID 9086149, PMID 9192643, PMID 9797827

NIH funding

R21AI180728 (1), U01AI068632 (1)